In 2020, the CRISPR/Cas9 technology was again thrown into the spotlight when it was announced that the inventors of the technology, Dr. Charpentier and Dr. Doudna, would receive the Nobel Prize in Chemistry for the discovery.

Bioneer has for more than 10 years worked with different cellular engineering technologies and early on switched to the CRISPR/Cas9 technology for gene editing in order to produce different kinds of cell-based disease models, mainly within CNS. Bioneer has for more than 10 years worked with different cellular engineering technologies and early on switched to the CRISPR/Cas9 technology for gene editing in order to produce different kinds of cell-based disease models, mainly within CNS.

Through the years our main focus has been to generate disease models based on induced pluripotent stem cells (iPSCs), but the CRISPR/Cas9 technology can be used in other cell lines as well. We have performed numerous gene edits and below list mentions some of the changes we have made:

  • Isogenic controls
  • Knockouts
  • Inducible Safe Harbor knockins
  • Reporter cell lines
  • Nucleotide changes

Today, we offer a whole package solution within CNS ranging from reprogramming, gene editing to assay development and screening services.

If you would like to discuss any CRISPR/Cas9 projects, contact Head of Cellular Engineering and Disease Models Bjørn Holst (mail) or Business Development Manager Lovisa M. Sunesson (mail).

To get an overview of Bioneer’s services within Disease models, follow the link.

Share this post